wild-type interleukin-12-expressing fibroblast activation protein chimeric antigen receptor T cell

This drug is a chimeric antigen receptor (CAR) T-cell therapy engineered to target fibroblast activation protein (FAP), a marker highly expressed on cancer-associated fibroblasts (CAFs) within the fibrotic tumor microenvironment. In addition to the CAR construct targeting FAP, these T cells are modified to secrete wild-type interleukin-12 (IL-12), a potent proinflammatory cytokine that stimulates anti-tumor immunity by activating cytotoxic T lymphocytes and natural killer cells. The dual mechanism involves the depletion of CAFs to disrupt the physical and biochemical barriers of the tumor stroma, followed by the localized delivery of IL-12 to enhance host immune infiltration and activation. In preclinical studies, this specific wild-type IL-12 construct has been utilized as a benchmark to evaluate next-generation variants, such as those featuring collagen-binding domain (CBD) fusions designed to improve cytokine localization and reduce systemic toxicity.

Other names

wt IL-12-expressing FAP CAR-Twild-type IL-12-expressing FAP-CAR-TFAP-CAR-T-wt-IL-12FAP-CAR-T-wt-IL12FAP-CAR-T-wt-IL 12